Instil Bio (TIL) Income from Continuing Operations (2020 - 2026)

Instil Bio has reported Income from Continuing Operations for 7 years, with the latest figure at -$6.5 million in Q2 2026.

• On a quarterly basis, Income from Continuing Operations rose 72.76% year-over-year to -$6.5 million in Q2 2026; TTM through Jun 2026 was -$40.5 million, a 55.93% increase from a year earlier, with the FY2025 full-year figure at -$80.6 million, down 6.63% from the prior year.
• Income from Continuing Operations was -$6.5 million for Q2 2026 at Instil Bio, up from -$7.9 million in the prior quarter.
• The five-year high for Income from Continuing Operations was -$6.5 million in Q2 2026, with the low at -$67.4 million in Q3 2023.
• Average Income from Continuing Operations over 5 years is -$30.5 million, with a median of -$23.9 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations tumbled 133.99% in 2022, then soared 76.0% in 2023.
• Over 5 years, Income from Continuing Operations stood at -$53.8 million in 2022, then jumped by 76.0% to -$12.9 million in 2023, then fell by 4.22% to -$13.5 million in 2024, then gained by 22.96% to -$10.4 million in 2025, then soared by 37.07% to -$6.5 million in 2026.
• The last three Income from Continuing Operations figures came in at -$6.5 million (Q2 2026), -$7.9 million (Q1 2026), and -$10.4 million (Q4 2025), per Business Quant data.